Focus: Eikon Therapeutics is a clinical-stage biotechnology company leveraging single particle tracking technology to develop novel oncology, ophthalmology, neurology, and gene therapy therapeutics. The company operates as a mid-cap biotech with an active pipeline spanning Phase 1–3 programs.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
13 added, 12 removed. Backfill posture.
Early-stage innovation opportunity with emerging clinical catalysts, but recent organizational turbulence and opacity around financial runway warrant due diligence on funding and leadership stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Eikon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eikon Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Eikon Therapeutics, Inc. (EIKN) (CIK 0001861123) — 8-K
8-K
Eikon Therapeutics Announces Recent Board Director Resignations - TipRanks
Eikon Therapeutics Announces Recent Board Director Resignations TipRanks
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down Stock Titan
8-K Filing: ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE) (CIK 0001035443) — EX-99.1
EX-99.1
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M Benzinga
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent layoff activity combined with board resignations (August 2026) suggests financial or strategic pressure; recommend verifying post-restructure headcount and funding runway before committing.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo